DuCap Xenograft Model Service for Prostate Cancer

The DuCap cell line provides a specialized and reliable in vivo platform for investigating the molecular mechanisms and therapeutic vulnerabilities of human prostate cancer. As a premier pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision DuCap Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your prostate cancer drug discovery and development pipeline.

Overview of DuCap Xenograft Model for Prostate Cancer

The DuCap xenograft model is an established in vivo translational system utilized in oncology research for the study of prostate adenocarcinoma. By transplanting human DuCap cells into immunodeficient rodent hosts, this model effectively reproduces the solid tumor growth characteristics, histopathological architecture, and proliferative patterns typical of human primary prostate malignancies.

Biologically, the DuCap model is valued for its consistent tumor formation and its distinct phenotypic profile, which provides a relevant genetic background for studying prostate carcinogenesis. This model preserves critical molecular features of human prostate cancer, including androgen receptor signaling capacity and sensitivity to a broad spectrum of experimental therapeutic agents. Consequently, the DuCap model is extensively deployed in pre-clinical screening programs to assess the anti-tumor potency of novel small-molecule inhibitors, targeted biological therapies, and combination treatment regimens in a physiologically relevant in vivo setting.

Fig 1. Success rates and cell culture dynamics of CRPC sublines. (Moll JM, et al., 2022)

Cell Line Information: DuCap

The DuCap cell line is derived from human prostate carcinoma tissue. These cells exhibit stable growth characteristics in vitro, making them a reliable and consistent choice for developing reproducible tumor models for prostate cancer research.

Our Services

Workflow of DuCap Xenograft Model Construction

• Cell Culture & Quality Control: Human DuCap cells are expanded in vitro using certified nutrient media under optimized physiological conditions. STR authentication and mycoplasma screening are performed prior to inoculation to ensure absolute genetic integrity and purity.
• Host Selection & Preparation: Immunodeficient rodent models are utilized for tumor engraftment, with all animals maintained in a controlled, pathogen-free environment to ensure physiological stability and consistency throughout the study.
• Precision Inoculation: A calibrated suspension of high-viability DuCap cells is prepared, often supplemented with an extracellular matrix (e.g., Matrigel) to optimize take rates. Cells are inoculated in vivo via subcutaneous injection into the host flank to facilitate the development of a measurable, solid tumor.
• Longitudinal Monitoring: Tumor dimensions are measured systematically using digital calipers to monitor volume progression. Animal health, activity, and body weight are recorded periodically to document systemic tolerance and clinical status.
• Randomization & Treatment: Once solid tumors reach a predefined, statistically significant volume, animals are randomized into experimental cohorts to ensure baseline parity before the initiation of customized therapeutic dosing regimens.

Fig 2. DuCap Xenograft Model Construction Workflow

Case Study - DuCap Xenograft Model Development

A pre-clinical validation study was conducted using the DuCap xenograft model to evaluate the therapeutic efficacy of a novel anti-prostate cancer candidate. Following the successful subcutaneous inoculation of DuCap cells into immunodeficient mice, the host animals developed firm, rapidly growing solid tumors. The treatment group demonstrated a clear, statistically significant inhibition of tumor growth compared to the vehicle-treated control group, confirming the model's high sensitivity and predictive reliability for screening novel prostate cancer interventions.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing specialized prostate cancer lineages, providing highly reproducible in vivo translational platforms for complex hormonal-resistance research.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready report providing comprehensive tumor growth metrics and statistical validations.

Contact us

Accelerating your prostate cancer drug pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our DuCap platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.